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Brian K Stansfield1,2,6* and David A Ingram3,4,5Abstract
Monocytes are primitive hematopoietic cells that primarily arise from the bone marrow, circulate in the peripheral
blood and give rise to differentiated macrophages. Over the past two decades, considerable attention to monocyte
diversity and macrophage polarization has provided contextual clues into the role of myelomonocytic derivatives in
human disease. Until recently, human monocytes were subdivided based on expression of the surface marker
CD16. “Classical” monocytes express surface markers denoted as CD14++CD16− and account for greater than 70%
of total monocyte count, while “non-classical” monocytes express the CD16 antigen with low CD14 expression
(CD14+CD16++). However, recognition of an intermediate population identified as CD14++CD16+ supports the new
paradigm that monocytes are a true heterogeneous population and careful identification of specific subpopulations
is necessary for understanding monocyte function in human disease. Comparative studies of monocytes in mice
have yielded more dichotomous results based on expression of the Ly6C antigen. In this review, we will discuss the
use of monocyte subpopulations as biomarkers of human disease and summarize correlative studies in mice that
may yield significant insight into the contribution of each subset to disease pathogenesis.
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Until the late 1980s, monocytes were considered to repre-
sent a single population of circulating hematopoietic cells
derived from the common myeloid progenitor cell in the
bone marrow. The seminal work of Passlik et al. demon-
strated that distinct monocyte subsets could be identified
based on the expression of the surface antigen CD16 [1].
“Classical” monocytes do not express the CD16 antigen
(CD14++CD16−), while “non-classical” monocytes are
smaller in size and express CD16 on the cell surface
(CD14+CD16++) [1]. The expression pattern of the two
surface markers lends some insight into their function.
CD14 acts as a co-receptor for toll-like receptor 4 and me-
diates lipopolysaccharide (LPS) signaling, while the CD16
antigen is identified as FcγRIIIa and participates in innate
immunity [2,3]. The subsequent two decades have yielded
considerable insight into the role of each cell population in
human disease; however, the recent emergence of an inter-
mediate monocyte population denoted as CD14++CD16+
has shifted focus away from this simple classification system* Correspondence: BSTANSFIELD@gru.edu
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reproduction in any medium, provided the orig[4-8] (Figure 1). As of 2010, three distinct monocyte popula-
tions outlined by Ziegler-Heitbrock et al. are officially
recognized: CD14++CD16− (classical), CD14++CD16+ (inter-
mediate), and CD14+CD16++ (non-classical) [4]. We will ad-
here to the official nomenclature for this review article.
Classical monocytes represent the largest population of
monocytes and are important scavenger cells [4]. Non-
classical monocytes were often referred to as pro-
inflammatory, secondary to their mobilization in disease
and secretion of important inflammatory cytokines [7,9-11]
(i.e. TNF-α). The new tripartite view of monocyte subpopu-
lations has shifted attention from the inflammatory charac-
teristics of non-classical monocytes and supports a more
significant role for intermediate monocytes in inflamma-
tion. Further, unique functions in angiogenesis, production
of reactive oxygen species, and patrolling behavior have
been attributed to CD16+ monocytes [12-18]. In the
present review, we will summarize the contribution of
monocyte heterogeneity in human disease and draw across
multiple common pathologies to characterize each mono-
cyte subtype for clinical relevance. We will focus on the im-
pact of monocytes in cardiovascular disease, including
myocardial infarction, atherosclerosis, and stroke, chronic
kidney disease, and autoimmune disease. Finally, we willr. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
inal work is properly credited.
Figure 1 Sample gating strategy showing three human monocyte populations based on expression of CD14 and CD16. Relative
expression of CD14 (x-axis) and CD16 (y-axis) is demonstrated on log scale. Classical monocytes (CD14++CD16−) are gated in the green box,
intermediate monocytes (CD14++CD16+) in the red box, and non-classical monocytes (CD14+CD16++) in the lavender box.
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their function in preclinical animal models to human
monocyte function.
Review
Monocyte ontogeny and heterogeneity
Genetic profiles, antigen expression, and cytokine produc-
tion of each monocyte population provide a foundation for
hierarchical clustering and classification. Cros et al. showed
that CD14+CD16++ monocytes (non-classical) are segre-
gated independently from intermediate and classical
monocytes based on principal component analysis [14].
Functionally, CD14++CD16− and CD14++CD16+ monocytes
are more phagocytic than non-classical monocyte [14]. Con-
versely, other investigators have provided genetic and func-
tional evidence to suggest that CD16+ monocytes cluster
together and are more distinct from classical CD16− mono-
cytes [7,16,19-21]. Wong et al. showed significantly different
genetic profiles between intermediate and classical mono-
cytes, which supported independent findings in humans and
rhesus monkeys [13,19,22]. Interestingly, cytokine produc-
tion in response to LPS in vitro reveals a more complex rela-
tionship. Intermediate monocytes produced significantly
more tumor necrosis factor-α (TNF-α) and interleukin-1β
(IL-1β) compared to the other populations; however, pro-
duction of interleukins 6, 8, and 10 were approximate in
intermediate and classical monocytes when compared to
non-classical monocytes [14,19].
Despite this controversy, stereotypic functions of classical
and non-classical monocytes are beginning to emerge.
CD14 is a pattern recognition receptor and classical mono-
cytes are critical components of innate immunity, while
CD16+ (intermediate and non-classical) monocytes are
preferentially mobilized during inflammation and lend totheir designation as “pro-inflammatory” [16,23,24]. The sig-
nificant functional overlap of intermediate monocytes with
classical and non-classical monocytes lends credence to the
present hypothesis that CD14++CD16− monocytes arise
from the bone marrow and give rise to CD14++CD16+ and
CD14+CD16++ monocytes [4,13,24]. CD14++CD16− mono-
cytes primarily produce monocyte chemotactic protein-1
(MCP-1/CCL2) and express its cognate receptor CCR2, as
do intermediate monocytes [14,22]. CCR2 is critical for
monocyte emigration from the bone marrow and monocyte
homing [25-29]. Likewise, CD62L (SELL), expressed on clas-
sical monocytes, is an important early marker of progenitor
cell commitment to specific progeny [30,31]. Population
specific genetic profiles reveal a progressive increase in
genes associated with maturation in intermediate and non-
classical monocytes when compared with classical mono-
cytes [19,24]. Finally, in response to macrophage colony
stimulating factor (M-CSF), intermediate monocytes are ini-
tially expanded in the peripheral blood followed by a delayed
increase in non-classical monocyte frequency [24,32,33].
Though not dogmatic, general recognition that classical
monocytes arise from the bone marrow and give rise to
intermediate and non-classical monocytes has provided a
platform for understanding monocyte maturation and
methods of replenishment in disease states. Table 1 outlines
the expression of surface markers for classical, intermediate,
and non-classical monocytes.
Presently, murine monocytes are evenly distributed by
their relative expression of the Ly6C antigen and are, for
the most part, functionally distinct [34-39]. Ly6Chigh
monocytes co-express CCR2 and CD62L with low ex-
pression of the fractalkine receptor CX3CR1, whereas
Ly6Clow monocytes have elevated expression of CX3CR1
with lower expression of CCR2 [39,40]. This expression
Table 1 Profile of human and mouse monocyte subpopulations
Human Mouse
CD14++CD16− CD14++CD16+ CD14+CD16++ Ly6Chigh Ly6Clow
CCR2a,b,c ++ + - ++ +
CX3CR1
a,b,c + ++ +++ + ++
CD62La,c ++ +/− - ++ -
CXCR1a,c ++ +/− - ND ND
CXCR2a,c ++ +/− - ND ND
PSGL-1d ++ + + ++ +
CD11ae,f + + ++ + ++
CCR5a,b,c + ++ - + +
ACEg + ++ + ND ND
HLA-DRa - ++ + ND ND
CD11ba + + +/− + +
CD11ce,h,i - + + - +
CD43f - + ++ + ++
MHCIIa,e,h + ++ + - +
aWong et al. Blood 2011; bRogacev et al. Eur Heart J 2011; cAncuta et al. JEM 2003; dAn et al. Circulation 2008; eIngersoll et al. Blood 2009; fZawada et al. Blood
2011; gUlrich et al. Nephrol Dial Transplant 2010; hSunderkotter et al. J Immunol 2004; iTanaka et al. Clin Exp Immunol 1999.
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are closely related to human classical (CD14++CD16−)
monocytes and conversely, Ly6Clow monocytes are
analogous to the non-classical CD14+CD16++ population
[14,19,24,40,41]. Bone marrow cells are enriched for the
Ly6C antigen and Ly6Chigh monocytes are capable of giving
rise to Ly6Clow monocytes and other derivatives in some
animal models [35,42-46]. However, Ly6Chigh monocytes
are preferentially recruited in inflammation and are the
major source of cytokines such as TNF-α and IL-1β
[36,37,40]. This departure from the functional description
of classical human monocytes requires resolution and may
be a function of current analytical techniques. For example,
separation techniques leverage the expression of human
monocyte markers to label each monocyte with differen-
tially expressing antibodies. The binding of these labeling
antibodies to poorly expressed surface antigens may pre-
clude their activation and underestimate cytokine produc-
tion and their response to various stimuli including LPS
[16]. Additionally, expression patterns of classic markers for
human monocytes (CD14, CD16, CD86, etc.) and murine
markers (Ly6C, CCR2, CX3CR1) are not directly analogous
between species. CCR2, for example, is preferentially
expressed on Ly6Chigh murine monocytes and has provided
evidence for their functional similarity to classical human
monocytes. However, CCR2 is expressed on Ly6Clow mono-
cytes as well, but is poorly expressed on human CD16+
monocytes [41]. Further, these simple murine monocyte
profiles (inflammatory vs. pro-inflammatory) likely limit
our ability to understand individual murine monocyte func-
tion and hinder translation to human studies. Ingersoll
et al. compared human CD16- and CD16+ monocytes withtheir murine counterpart to show that multiple pro-
inflammatory and phagocytic antigens (TREM-1, CD64 and
CD36) were highly expressed on Ly6Clow monocytes and
approximated relative expression in CD16- human mono-
cytes [41]. However, antigen expression patterns and gen-
omic data mostly confirm the present grouping of Ly6Chigh
monocytes with CD14++CD16− human monocytes
[14,40,41]. Several recent reviews attempt to resolve this
controversy [24,39,40].
Monocytes phenotypes in cardiovascular disease
Expansive remodeling and leukocyte infiltration of the
left ventricle in response to coronary artery occlusion
is predictive of poor outcomes [40,47]. Monocyte
mobilization during the evolving infarction and recovery
period follow a sequential pattern. Tsujioka et al. studied
the mobilization of CD16− and CD16+ monocytes during
the natural progression of acute myocardial infarction
(AMI) in a Japanese patient population [48]. Circulating
CD16+ monocytes were diminished in patients diag-
nosed with AMI at the time of admission and rose sig-
nificantly over the first week after diagnosis. The
mobilization of CD16+ monocytes was preceded by
increased CD14++CD16− monocytes in the first days fol-
lowing AMI admission. Circulating monocyte popula-
tions did not differ between groups; however, peak
levels of CD14++CD16− monocytes were a negative pre-
dictor of myocardial salvage and no relationship be-
tween CD16+ monocytes and infarction size was noted
in this study [48]. Other human studies and murine
models of myocardial infarction support these findings
[50-53]. Ly6Chigh monocytes, corresponding to classical
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diately after AMI and are followed by a recovery period
denoted by expansion of Ly6Clow monocytes (analogous
to human non-classical monocytes) [50,54]. However,
characterization of human monocyte mobilization in
Tsujioka et al. is difficult to interpret, as CD16+ monocytes
were not distinguished into intermediate and non-classical
populations [48]. Recently, monocyte subtypes were ana-
lyzed in a cohort of patients admitted for AMI and com-
pared to patients with stable coronary artery disease
(CAD) and a second cohort of healthy controls [55]. Pa-
tients admitted for AMI had a 60-80% increase in total
monocyte count and a disproportionate increase (3-fold)
in intermediate (CD14++CD16+) monocytes when com-
pared with patients admitted with CAD and healthy con-
trols. The intermediate monocyte population remained
elevated for the subsequent 7 days after AMI and trended
to background control levels by day 30. The authors go on
to show that return of the intermediate monocyte popula-
tion to normal frequency correlated with decreased tropo-
nin levels and return of left ventricular ejection fraction
[55]. These smaller cohort studies are supported by a large
prospective cohort study of persons undergoing angiog-
raphy. Intermediate monocyte frequency strongly corre-
lated with a composite outcome of cardiovascular death,
non-fatal AMI, and non-hemorrhagic stroke in 951 pa-
tients. A planned secondary analysis revealed that patients
with the highest frequency of intermediate monocytes had
a 40% risk of experiencing a cardiovascular event within
three years of study enrollment [49]. Collectively, clinical
studies suggest an intriguing role for monocyte differenti-
ation as a diagnostic and predictive biomarker in patients
suffering AMI.
Similar to the findings observed in patients suffering AMI,
a characterization study of human monocyte mobilization in
the days following a stroke revealed an expansion of
intermediate monocytes by day 2, while the classical
monocyte population was unperturbed [56]. Non-classical
CD14+CD16++ monocyte frequency inversely mirrored
intermediate monocyte frequency and reached the nadir by
day 2 after stroke. The classical monocyte population was
lower at the time of admission for stroke in surviving pa-
tients and correlated with improved prognosis. Intermediate
monocyte mobilization over the subsequent 48 hours fol-
lowing stroke also correlated with stroke severity and in-
creased mortality rates, which held significance following
adjustment for age and stroke severity scoring [56,57]. A
second cohort of 36 stroke patients supported the increased
frequency of intermediate monocytes in the peripheral blood
in the days to weeks following infarction; however, Kaito
et al. showed that classical monocyte numbers increased im-
mediately following presentation for stroke [58]. A positive
correlation with stroke severity score in this study was also
observed and may be explained by a strong association withprogressing infarction [58]. Thus, assessment of monocyte
subsets following admission for stroke may show a time-
dependent predictive value in outcomes and survival.
Monocytes in chronic cardiovascular inflammation
Atherosclerosis is the result of complex interactions be-
tween circulating leukocytes and the vascular wall, which
are likely propagated by chronic secretion of growth factors
and inflammatory cytokines. The lack of true homology be-
tween murine and human monocyte subpopulations limit
the direct application of findings in murine atheroma to
that observed in human cohorts. Ly6Chigh monocytes, the
murine correlate of human classical monocytes, drive ath-
erosclerosis in transgenic animal models based on the gen-
etic deletion of apolipoprotein E or the LDL receptor
[26,37,45,59-61]. Ly6Chigh monocytes preferentially bind to
the activated endothelium in atherogenic ApoE knockout
mice and infiltrate the developing atheroma to give rise to
lesional macrophages and, eventually, foam cells [26,37].
Comparatively, CD16+ monocytes are primarily implicated
in human atherosclerosis. Increased frequency of non-
classical monocytes, in association with other markers of
dyslipidemia, has been demonstrated in multiple human
studies [24,62,63]. Non-classical monocytes are mobilized
in patients with hypercholesterolemia and their frequency
in the peripheral blood appears to be directly correlated
with total cholesterol and triglyceride level and inversely
proportional to HDL concentration [62-64]. Recent work
attempting to differentiate the contribution of CD16+
monocytes to atherosclerosis show that intermediate
monocyte frequency is closely related to severity of angina
and may contribute to atherosclerosis [65,66]. These find-
ings have implications on therapeutic efficacy since mono-
cyte subpopulations have variable expression of scavenger
receptors that participate in cholesterol uptake and metab-
olism. For instance, an early randomized trial targeting
hypercholesterolemia showed that statin treatment (fluvas-
tatin) increased CD16+ monocytes [63]. Other studies have
not identified a similar increase in non-classical monocytes
following initiation of a statin (rosuvastatin, atorvastatin,
and pivastatin), which may suggest class-dependent effects
on monocyte frequency [67,68].
To compound the difficulty of interpreting these studies,
the vast majority of human studies failed to include the
intermediate monocyte population in their analysis. Re-
cently, intermediate monocyte frequency was identified as a
positive predictor of major cardiovascular event in two large
European cohorts of 438 and 951 patients [49,69]. Further,
intermediate monocyte frequency negatively correlated with
HDL and Apo-1 [49,69], which is likely consistent with pre-
vious clinical studies demonstrating an association between
CD16+ monocytes and markers of dyslipidemia. These find-
ings are particularly intriguing since intermediate mono-
cytes may possess significant inflammatory properties and
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classical monocytes. Intermediate monocytes express CCR2
and CCR5, which are critical for monocyte homing and
trans-endothelial migration into the atherosclerotic plaque
[26,27,61,70]. Genetic deletion of CCR2 or CCR5 in ApoE
knockout mice significantly reduces atherosclerosis and
monocyte mobilization [71-75]. Further exploration of the
relationship between intermediate (CD14++CD16+) mono-
cytes and atherosclerosis will significantly advance our un-
derstanding of pro-atherogenic conditions and aide in the
design of novel cell-directed therapies for the treatment of
atherosclerosis.
Obesity represents a chronic inflammatory state that
increases the risk for heart disease and stroke by greater
than fifty percent [76,77]. Several groups have inde-
pendently demonstrated that the frequency of non-
classical and intermediate monocytes positively corre-
lates with WHO obesity classification and fat mass
[24,64,78-80]. In fact, a cohort of 105 subjects with
WHO class II and III obesity had an increased fre-
quency of non-classical and intermediate monocytes in
the peripheral blood compared to healthy controls; a
finding that was not observed in WHO class I subjects
[64]. A modest 5% reduction in fat mass significantly
reduced non-classical monocyte frequency and im-
proved glycemic control in obese diabetic patients [64].
Not surprisingly, the vast majority of positive correlative
studies between non-classical monocyte frequency and
cardiovascular disease loose statistical significance in
post-hoc analysis correcting for BMI. These epidemio-
logic observations in human cohorts provide evidence
for a direct link between adiposity, inflammation, and
monocyte maturation.
Animal models of metabolic disease may provide
some clues to the connection between obesity and vas-
cular inflammation. ApoE knockout (ApoE−/−) mice
provided a high fat western diet develop morbid obesity
and have evidence of chronic inflammation. Loss of
ApoE expression in hematopoietic cells appears to drive
monocyte proliferation, mobilization, and differentiation
in the development of atherosclerosis [81]. ApoE−/− mice
on high fat diet (HFD) developed a time-dependent expo-
nential increase in Ly6Chigh monocyte frequency in the
peripheral blood and spleen compared to wildtype mice
on HFD [37]. Ly6Chigh monocytes rapidly incorporated
into the developing atheroma and accounted for the vast
majority of lesional macrophages [37,45]. However, local
macrophage turnover within atheroma may drive foam
cell formation independent of monocyte recruitment
[36]. Several studies have demonstrated that ApoE in-
teracts with the ATP-binding cassette transporters (i.e.
ABCA1) to coordinate cholesterol efflux and monocyte
recruitment [81-83]. Loss of ABCA1, and other choles-
terol transport proteins, accelerates lesion formationand likely participates in myeloid cell proliferation and
function.
Recent attention to the role of adventitial adipose tissue,
termed perivascular adipose tissue or PVAT, provides a
novel look at the relationship between adiposity and vascu-
lar inflammation. Perivascular adipocytes secrete growth
factors and adipokines that stimulate an inflammatory re-
sponse by recruiting monocytes and other leukocytes to the
vascular wall [84-88]. Precursor and differentiated adipo-
cytes accumulate near atheroma in the perivascular adven-
titia of conduit vessels and expand with obesity [86].
Monocyte chemotactic protein-1 (MCP-1/CCL2) is highly
secreted by perivascular adipocytes and is a potent mitogen
for circulating monocytes [85,89]. Genetic deletion of
MCP-1 in mice impedes macrophage infiltration and lipid
deposition following arterial injury [85]. Interestingly,
MCP-1 is sequentially expressed in the adventitia followed
by the media and intima after coronary artery injury, sug-
gesting a central role for perivascular adipocytes in mono-
cyte recruitment [90]. These data provide evidence that
perivascular adiposity, along with visceral and subcutaneous
fat, participate in vascular inflammation and monocyte
chemotaxis. How perivascular adipocytes interact with cir-
culating hematopoietic cells and isolating their effect on
leukocyte recruitment from other fat stores in vascular in-
flammation are important future areas of investigation.
Monocyte subpopulations in kidney disease
Chronic kidney disease (CKD) is closely related with car-
diovascular health and commonly exists as a co-morbid
condition in persons with cardiovascular disease. Persons
with CKD often suffer from atherosclerosis and are at in-
creased risk for mortality following an acute cardiovascular
event [91,92]. Patient cohorts have uniformly demonstrated
that increased intermediate (CD14++CD16+) monocyte
frequency is associated with cardiovascular event rate
and increased mortality [70,78,93-95]. A study of 119 pa-
tients with CKD demonstrated an increased frequency of
intermediate monocytes in the peripheral blood of
hemodialysis-dependent CKD patients compared to CKD
patients with adequate native renal function [70]. Depletion
of intermediate monocytes during hemodialysis was associ-
ated with an increased cardiovascular event-free period and
reduced mortality in patients with end-stage renal disease
[70,96]. Classical and non-classical monocytes have failed
to show a correlation with mortality in CKD patients re-
gardless of the need for hemodialysis. Subgroup analysis
identified intermediate monocytes expressing angiotensin-
converting enzyme (ACE) were significantly higher in CKD
patients with severe atherosclerosis and may yield add-
itional prognostic value [94-96]. Increased ACE expression
in intermediate monocytes has also been demonstrated in
patients with abdominal aortic aneurysm and appeared to
be independent of CKD classification [97]. While the role
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known, the renin-angiotensin system is critical for mono-
cyte maturation and function and targeting this signaling
axis may be of therapeutic benefit in monocyte-driven hu-
man disease [98,99]. Along this line of inquiry, a small co-
hort of dialysis-dependent CKD patients was randomized
to an angiotensin receptor 1 blocker (losartan) or other
anti-hypertensive medication and monocyte populations
were evaluated. The losartan group showed a reduction of
CD16+ monocytes in their peripheral blood after two
months of therapy compared to patients receiving antihy-
pertensive medication that did not target the renin-
angiotensin axis [100]. The authors demonstrate that the
CD16+ monocytes produced TNF-α in vitro; however their
gating strategy failed to distinguish intermediate and non-
classical monocytes within the CD16+ population. While
CD14++CD16+ monocytes appear to be an important bio-
marker of CKD severity, their role in the evolution of CKD
is yet to be determined.
Monocytes and autoimmune disease
Monocyte-mediated inflammation has long been targeted
in the treatment of rheumatoid arthritis. Attention to
monocyte heterogeneity has expanded our understanding
of rheumatologic diseases and provided new interventions
for patients. Most groups have demonstrated an expan-
sion of CD16+ monocytes in patients with rheumatoid
arthritis with the recent delineation of CD16+ subpopula-
tions strongly suggesting that CD14++CD16+ monocytes
are the principle inflammatory effectors [21,101,102].
CD16+ monocytes are found in the synovial fluid of RA
patients and are associated with joint destruction [101].
Elevation of the CD16+ monocyte frequency in RA
patients was recently demonstrated to be primarily an
expansion of the intermediate population [21]. Sequester-
ing the inflammatory properties of CD14++CD16+ mono-
cytes may inhibit joint injury and signify response to
therapy. Monoclonal antibodies directed against TNF-α
(Inflixamab, Adalimumab, Etanercept) have been ex-
tremely effective in the treatment of RA and may target,
in part, intermediate and non-classical CD16+ monocytes.
A comparison study of anti-TNF-α antibodies demon-
strated a reduction in CD14++HLADR+ monocytes in RA
patients taking infliximab that the authors suggest may ac-
count for the increased sepsis event rate noted in this
study population [103]. HLADR is an important third
marker (along with CD86) that is highly expressed on
intermediate monocytes and less so on non-classical
monocytes [104]. A larger cohort of RA patients (111
total) showed a slight, but non-significant increase in
intermediate monocyte frequency in early RA that was
profoundly increased in RA patients with long-standing
disease [105]. In response to treatment with methotrexate,
the authors identified that CD16 expression on CD14++monocytes was a negative predictor of response after
14 weeks of therapy. Both RA patients with and without a
history of treatment with immune modulating agents
showed a negative correlation between intermediate
monocyte frequency during treatment and disease activity
scores [105]. These clinical studies suggest that intermedi-
ate monocyte frequency may predict response to therapy
and side effect profile in RA patients using immunosup-
pressive therapy. However, cytokine production has not
been linked to monocyte subpopulation frequency in RA
patients during active disease or following treatment.
Therefore, the use of monocyte markers as a biomarker
for therapeutic response remains limited.
Similar to RA patients, CD16+ monocytes are preferen-
tially expanded in persons with both Crohn’s Disease (CD)
and ulcerative colitis [11,106,107]. Grip et al. showed a
spike in intermediate monocyte frequency in CD patients
with active disease, which was marked by increased expres-
sion of CCR2 on the intermediate monocyte population.
Classical and intermediate monocytes expressed similar
levels of CCR2 during active disease and the expression
pattern of CCR2 on the intermediate monocyte population
in CD patients was significantly elevated compared to the
expression of CCR2 on matched healthy controls [11].
These findings are intriguing and suggest that monocytes,
within a sub-classification system, may have alternative
phenotypic signatures in response to inflammation. Further,
this data supports the independent finding that MCP-1
(CCL2) levels are increased in patients with inflammatory
bowel disease and correlate with disease severity [108,109].
Recently, Thiesen et al. showed enhanced migration of clas-
sical monocytes isolated from CD patients in response to
MCP-1 (CCL2) and increased CD14 expression in macro-
phages isolated from inflamed intestinal mucosa of CD pa-
tients [110]. The CD14++ HLADRlow macrophages isolated
from the colon of CD patients expressed high levels of
CD62L which supports a classical monocyte origin, how-
ever, these macrophages also expressed the fractalkine
receptor CX3CR1 which is more characteristic of non-
classical monocytes [110]. Other groups have found a more
pronounced infiltration of CD16+ monocytes in actively
inflamed tissue from CD patients that corresponded with
increased staining for TNF-α [107]. Resolution between
these findings may again point back to an integral role for
intermediate monocytes in active CD.
Gaps and future directions in understanding monocyte
heterogeneity
Recent adherence to the tripartite description of monocytes
based on expression of CD14 and CD16 along with stan-
dardized gating strategies has enabled investigators to more
thoroughly explore the nature of monocyte differentiation
and function in human disease. However, the recognition
of an intermediate population that most truly represents an
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demonstrating expansion of classical and non-classical
monocytes during inflammation. Thus, a re-examination of
previous clinical studies and human cohorts with a uniform
gating strategy and consistent use of approved nomencla-
ture is warranted.
Though evidence of monocyte mobilization in human
disease has now been demonstrated, the question of
whether their rise is consequential of the illness/inflamma-
tion or directly contributes to the inflammatory process re-
mains largely unanswered. In particular, does the increase
in CD16+ monocyte (intermediate and non-classical) fre-
quency observed in cases of both acute and chronic inflam-
mation result from increased differentiation or do they
arise independently in response to inflammatory signaling
cascades. Human studies addressing these questions will
likely focus on chronic diseases with periodic episodes of
acute inflammation (i.e. autoimmunity), as several groups
have pointed out that classical monocytes appear to exhibit
a progressive increase in CD16 expression during acute ill-
ness [107,111,112]. A particularly interesting subset of these
patients includes those with disease primarily affecting a
single organ such as RA or Crohn’s Disease. Comparative
studies of monocyte frequency between the peripheral
blood and diseased organ have generated promising data
supporting the maturation of these monocytes in the per-
ipheral blood prior to infiltration. Further, does the spleen
function as a monocyte reservoir for mobilization during
periods of acute inflammation as has been observed in mice
[45]? Supportive in vitro characterization of all monocyte
populations, especially the intermediate subset, will help de-
fine the inflammatory signature of each population and
may lead to the designation of a true pro-inflammatory
monocyte. Specific therapeutic targeting of the offending
monocyte population may limit the need for treatments
that indiscriminately target all monocytes and the import-
ant side effect profile associated with these types of ther-
apies. Finally, could preferential recruitment of a less
inflammatory monocyte population limit inflammation
and promote healthy repair?
Conclusions
Recognition of three monocyte populations with diversified
and heterogeneous responses in health and disease has in-
creased mechanistic insight into the pathogenesis of inflam-
mation as it relates to both chronic and acute illness. The
more dichotomous murine monocyte populations, denoted
as Ly6Chigh and Ly6Clow, hinder the ability to directly trans-
late animal findings to humans. Careful mechanistic and
lineage tracing studies in mice and humans will enhance
our understanding of monocyte function in health and dis-
ease. At present, the intermediate monocyte population ap-
pears to represent an inflammatory monocyte population
and therefore harnessing the inflammatory capacity ofintermediate monocytes may promote a healthy response to
injury or inflammation. Selective depletion of intermediate
monocytes requires a highly specific surface marker regi-
men. Therefore, uniform adoption of the recommended gat-
ing strategies and nomenclature for proper identification of
each monocyte subpopulation is necessary to provide a clear
picture of their role in human disease [4,5,24].
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